GlaxoSmithKline (GSK Plc)

🚨 Reasons for Boycotting GSK (GlaxoSmithKline)

GSK plc (GlaxoSmithKline) is a publicly traded British multinational pharmaceutical company formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, headquartered in Brentford, London, United Kingdom. The company operates in vaccines, prescription medicines, and consumer healthcare. GSK operates directly in israel through its 100%-owned subsidiary GlaxoSmithKline (israel) Ltd. The subsidiary is headquartered in Petach Tikva, israel. Through its israeli office, clinical research, and scientific collaborations, GSK directly contributes to the israeli economy and occupation infrastructure. Additionally, the company's largest institutional shareholders include major Zionist-aligned investment funds such as BlackRock and Vanguard.

1. Direct Subsidiary in israel: GlaxoSmithKline (israel) Ltd.: GSK operates in israel through a subsidiary called GlaxoSmithKline (israel) Ltd. This subsidiary is 100% directly owned by GSK. Its headquarters are in Petach Tikva, israel (25 Basel Street, PO Box 10283, Petach-Tikva 49002). GSK conducts office, clinical research, and scientific collaboration activities in israel. The israeli office focuses on GSK's four therapeutic areas: infectious diseases, HIV, oncology, and immunology. This direct presence demonstrates the company's corporate-level integration into the israeli economy.GSK: israel — Petach Tikva-based office (2026)GSK Supplier: GlaxoSmithKline (israel) Ltd — 25 Basel Street, Petach-Tikva (2026)
2. Patent Dispute and Settlement with Teva: The legal dispute between GSK and israel-based Teva Pharmaceutical Industries was a patent lawsuit that began in 2007 and lasted over a decade. The case revolved around GSK's heart medication Coreg (carvedilol) and the "skinny labeling" practice. Teva launched a generic version of Coreg in two indications in 2007; GSK sued in 2014 after Teva added a third indication (congestive heart failure). The Delaware District Court awarded GSK a $235 million verdict against Teva in 2017, which was later overturned and reinstated. Teva petitioned the Supreme Court, but the Supreme Court declined the case in May 2023. Finally, in February 2026, GSK and Teva settled their dispute, dropping all claims and closing the case. Additionally, Teva entered a generic manufacturing agreement with GSK for diabetes drugs (Avandia, Avandamet, Avandaryl), entering the US market in 2012. These cases reveal GSK's legal and commercial ties with israel-based pharmaceutical companies.Fierce Pharma: GSK and Teva settle Coreg dispute (February 2026)Pharmacy Times: Teva settles GSK diabetes drugs (November 2007)ET HealthWorld: Supreme Court rejects Teva appeal (2023)
3. Other israel Connections: GSK's ties to israel are not limited to its subsidiary:
   • NanoPass Technologies: GSK signed an agreement with Haifa, israel-based NanoPass Technologies to develop MicroPyramid technology for vaccine delivery.
   • Academic Collaboration: In 2013, a delegation of GSK scientists visited israel to foster cooperation with israeli academic scientists.
   • Funding for israeli Patient Organizations: GSK regularly provides donations and funding to israeli patient organizations such as the israel AIDS Task Force (€30,953 in 2022, €28,810 in 2021, £25,250 in 2017).
   • Consumer Healthcare Subsidiary: GSK Consumer Healthcare israel Ltd. is also registered in israel at the same address.Manufacturing Chemist: GSK and NanoPass Technologies agreement (2024)GSK: Funding for israeli patient organizations (2022)GOV.UK: GSK delegation met israeli scientists (February 2013)
4. Zionist Capital: BlackRock and Vanguard Shareholding: The largest institutional shareholders of GSK plc include BlackRock, Inc. (9.40%) and Vanguard Capital Management, LLC (4.02%). BlackRock is GSK's single largest shareholder. This demonstrates that the company is strongly supported by major investment funds that form the backbone of Zionist capital. BlackRock and Vanguard's investments in israel-linked companies indirectly contribute to sustaining the occupation economy.Investing.com: GSK — BlackRock 9.40%, Vanguard 4.02% (2026)ADVFN: GSK — largest institutional shareholders (2026)
5. Boycott Status and Petach Tikva Settlement: GSK is not on the BDS movement's official boycott list. However, independent boycott platforms and activist groups boycott the company due to its direct presence in israel, cooperation with israeli institutions, and funding for israeli patient organizations. The location of GSK's israeli office, Petach Tikva, is noted as an illegal settlement established in 1878 on the former Palestinian village of Mlabes. This indicates the company's physical integration into the occupation infrastructure.Gaza.nu: GSK — not on official BDS list (2026)Notion: GSK — Petach Tikva illegal settlement (2026)

🌐 Sources

• GSK Official Website
• Fierce Pharma: GSK and Teva dispute
• Investing.com: GSK Ownership Structure
• Manufacturing Chemist: GSK and NanoPass
• Notion: GSK israel Connections
• Gaza.nu: GSK Boycott Status

Boykot Market has listed the brand information and source links above based on verifiable official sources. Please conduct your own research to be certain.